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Abstract 
Non-animal source hyaluronic acid (Restylane®) is a relatively new redefining 
dermal filler that is being employed with increasing frequency in the fields of 
dermatology and cosmetic/facial plastic surgery.  
We report a case of a 74-year-old woman who presented with a firm 
submucosal nodule of the lower lip, which clinically was thought to represent a 
benign neoplasm. An excisional biopsy revealed the presence of multiple cyst-like 
vacuolated areas surrounded by granulomatous tissue composed predominantly of 
histiocytes and foamy macrophages, consistent with a foreign body reaction. 
Subsequent to the pathology findings, the patient acknowledged that she had 
received injections of Restylane® to the lips approximately 6 months before 
discovering the nodule. She had not mentioned this to her dentist or oral and 
maxillofacial surgeon to whom she had been referred because she believed that 
these two events were not related.  
Although hyaluronic acid-based dermal fillers reportedly have a low incidence of 
long term side effects, clinicians should be aware of the possible development of 
foreign body reactions to these injectable agents. 
Introduction 
A substantial amount of research has been directed towards the development 
of a biocompatible material with prolonged clinical longevity for use as an esthetic 
facial soft tissue augmentation agent. Some of these skin fillers include autologous 
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fat, bovine collagen, as well as autologous and allogeneic human collagen. Until 
recently, bovine collagen has been regarded as the “gold standard” in facial soft 
tissue augmentation. However, bovine collagen has a number of significant 
limitations, including the development of delayed hypersensitivity reactions in 
approximately 3% of patients1. As a result, double skin testing is recommended prior 
to treatment with bovine collagen2. 
Hyaluronic acid-based temporary dermal fillers are being employed with 
increasing frequency for the treatment of facial skin lines and for lip augmentation 
procedures. These include Restylane® (Q-Medical Corporation, Uppsala, Sweden), 
a cross-linked hyaluronic acid injectable filler produced from bacteria by microbiologic 
engineering techniques3, and Hylaform® (Biomatrix Inc., Ridgefield, NJ), a hyaluronic 
acid extract derived from rooster combs.  
Hyaluronic acid, a glycoaminoglycan consisting of repeating units D-glucuronic 
acid and N-acetyl-D-glucosamine, is a major component of the extracellular matrix of 
the dermis. In contrast to collagen, the chemical structure of hyaluronic acid is 
reportedly identical across species4. Therefore, the risk of imunogenicity to these 
products is believed to be low. However, these products do contain trace amounts of 
hyaluronin-associated protein and, in the case of Restylane®, bacterial antigens5. 
Moreover, the cross-linking process may introduce some immunogenic potential. 
 
Case Presentation 
A 74-year-old woman presented with a firm, submucosal nodule of the lower lip 
measuring approximately 1.5cm in diameter. Clinically, this was thought to represent a 
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benign neoplasm. An excisional biopsy was performed under local anesthesia. The 
excised mass measured 1.2 x 1.2 x 0.8cm. Histologic examination revealed mucosa 
overlying connective tissue containing multiple vacuolated cyst-like areas (Figure 1). 
These cyst-like structures were surrounded by a granulomatous foreign body tissue 
reaction composed predominantly of histiocytes and foamy macrophages (Figure 2). 
On further questioning, the patient acknowledged that she had received injections of 
Restylane® to the lips by a dermatologist approximately 6 months before the 
development of the nodule. She had not mentioned this to her dentist or oral surgeon 
because she believed that these two events were not related. The patient denied 
having any prior cosmetic procedures to the face or lips besides the Restylane® 
injections.  
On follow-up the surgical site had fully healed, and no further soft tissue nodules 
or swellings were noted.  
 
 
Discussion 
The incidence of long term adverse reactions secondary to the injection of 
hyaluronic acid skin fillers is low. Short duration local injection site reactions, 
consisting of swelling, pain, tenderness and bruising are seen in the vast majority of 
patients treated with injectable hyaluronic acid derivatives2. In the same study, 
delayed onset reactions, primarily redness which resolved without treatment within 3 
months, were noted in 8% of patients treated with Restylane®.  
A review6 of all reports of adverse reactions to Restylane® submitted to the 
manufacturer in 1999 and 2000 estimated one adverse event for every 650 to 1800 
patients treated. These consisted primarily of localized hypersensitivity reactions and 
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injection site inflammation. There were two cases of injection site necrosis, as well as 
“rare reports of localized granulomatous reactions, bacterial infections, as well as 
acneiform and cystic lesions”6. 
A retrospective study5 of an estimated 4300 patients injected with Restylane® 
documented a 0.6% incidence of hypersensitivity reactions, equally divided between 
immediate and delayed reactions. 
In a prospective randomized study of 38 individuals treated with Restylane® 
alone or Restylane® with Botulinum toxin A3, one subject in the combined 
Restylane®/ Botulinum toxin A group developed two episodes of delayed erythema, 
swelling and discomfort at the injection site at 4 and 11 months. A review of 709 
patients1 treated with either Hylaform or Restylane® for smoothing of nasolabial and 
glabellar lines, lip augmentation and correction of atrophic facial scars noted that 
slightly less than 0.5% of patients developed delayed skin reactions. The delayed 
skin reactions, which were first noticed between 6 to 8 weeks after injection, were of 
varying severity and manifested as induration, erythema and tenderness at the 
injection sites. One patient developed a sterile abscess of the nasolabial region. Time 
to complete resolution varied from 6 to 24 weeks. Three patients were treated with 
intralesional injections of triamcinolone. Subsequent intradermal skin testing 
performed on these patients was positive in 4 of 5 patients tested1. 
A number of anecdotal reports of adverse reactions following dermal infiltration 
with hyaluronic acid-based fillers have been published. Shafir and Amir7 described a 
patient who developed multiple sterile abscesses following injection of both lips and 
the nasolabial folds with Restylane®. A single report of a patient developing a 1x1 cm 
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ulcer of the glabellar region following injection with Restylane® has also been 
described8. The authors ascribed this reaction to embolization of the dorsal nasal 
artery by the injected hyaluronic acid gel. Low9 described a case of venous occlusion 
of the upper lip with a resulting varix that persisted for 6 years following injection with 
Restylane®. Lupton and Alster10 reported a case of a woman who developed 
multiple erythematous papulocystic nodules following injection of an unspecified 
modified hyaluronic acid gel. Toy and Frank11 presented 2 case reports of women 
who developed granulomatous infections following injections of an unlicensed 
hyaluronic acid derivative (Hyacell) imported from South America. Both women were 
injected by the same practitioner, who was practicing medicine without a license in 
New York City. This individual was ultimately tied to a cluster of Mycobacterium 
abscessus infections, presumably related to injections with tainted hyaluronic acid11. 
Histologic findings associated with adverse reactions to hyaluronic acid dermal 
injections have only been described in a few cases. In the previously described study 
by Carruthers and Carruthers3, histologic examination performed on one patient 
treated with Restylane® revealed a moderate lymphocytic and plasma cell infiltrate in 
the mid to lower dermis. No foreign material or foreign body giant cells were noted. 
Alcian blue staining for hyaluronic acid was negative. Fernandez-Acenero and 
colleagues12 biopsied a nodule of the upper lip in a patient who received injections of 
Restylane® 2 months prior. A giant cell granulomatous foreign body reaction 
surrounding pools of Alcian blue positive amorphous material was noted. Soparkar et 
al13 performed an incisional biopsy on a 65-year-old female patient who developed 
multiple plaque-like elevations of the periorbital region 5 years after undergoing 
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cosmetic treatment with Restylane®. Histologic examination revealed the presence 
of multiple cyst-like spaces, some of which contained alcian blue positive material, 
with a surrounding fibrotic reaction. Interestingly, they reported resolution of the 
dermal elevations following local infiltration of hyaluronidase. Follow-up histologic 
examination was not available. Raulin and colleagues14 performed an intracutaneous 
test on a 53 year-old woman who developed a granulomatous-like lesion after 
injection of Hylaform for correction of perioral wrinkles. A biopsy taken 30 days later 
from the intracutaneous test site revealed the presence of a foreign body granuloma 
as well as the presence of mucin-like basophilic material presumed to be hyalform. 
Rongioletti et al15 performed a biopsy on a 72-year-old woman who developed 
induration of the skin after receiving injections of Restylane®. The biopsy specimen 
revealed a foreign body granulomatous reaction encircling clear spaces of variable 
size, reminiscent of the histologic pattern seen in our patient. Alcian blue positive 
material was identified in the sclerotic stroma, but not in the clear vacuolated areas. 
Due to the histologic resemblance of the biopsied specimen to a silicone foreign body 
reaction, infrared spectrophotometry was performed to rule out the possibility of 
adulteration of the injected filler with silicone. Micheels16 reported biopsy findings on 
four patients who experienced delayed reactions following cosmetic treatment with 
hyaluronic acid derivatives. Three biopsies from areas treated with Hylaform all 
exhibited foreign body-type giant cell reactions. Of the two areas injected with 
Restylane®, one showed a strong foreign body-type giant cell reaction, similar to the 
pattern noted following Hylaform injection. The other Restylane® injection site 
revealed mild chronic inflammation. Honig and colleagues17 reported a foreign body-
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type giant cell reaction developing in a woman who received injections of hyaluronic 
acid in the nasolabial fold for the correction of facial lines. The most comprehensive 
histopathologic assessment of orofacial foreign body granulomas following injection 
of a number of different cosmetic fillers was reported by Lombardi et al18. However, 
none of the biopsied lesions were from patients treated with hyaluronic acid-derived 
fillers. 
 
 
Conclusion 
Although hyaluronic acid-based dermal fillers reportedly have a low incidence of 
long term side effects, clinicians should be aware of the possible development of 
foreign body reactions to these injectable agents. When presented with a patient with 
a nodular lesion of the lips or facial region, the possibility that the patient may have 
undergone previous cosmetic procedures to the area should be included in the 
differential diagnosis. 
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Figure 1: Low Power View of Biopsy Specimen from Lower Lip. Multiple vacuolated 
cyst-like areas of different size are evident. These are surrounded by fibrotic connective 
tissue and a histiocytic tissue reaction. (Hematoxylin and eosin, original magnification 10x). 
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 Figure 2: High Power View of Biopsy Specimen from Lower Lip. Fibrotic tissue and 
histiocytes surround the variable sized, vacuolated cyst-like areas. Abundant histiocytes are 
evident. (Hematoxylin and eosin, original magnification 40x). 
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